(Q21004071)

2

Gabor E

Linthorst

2 references

8 July 2022

11 July 2022

Gunnar Houge

3

Gunnar

Houge

2 references

8 July 2022

11 July 2022

Johannna E M Groener

4

Johannna E M

Groener

2 references

8 July 2022

11 July 2022

Els E Ormel

5

Els E

Ormel

2 references

8 July 2022

11 July 2022

Berto J Bouma

6

Berto J

Bouma

2 references

8 July 2022

11 July 2022

Johannes M F G Aerts

7

Johannes M F G

Aerts

2 references

8 July 2022

11 July 2022

Asle Hirth

8

Asle

Hirth

2 references

8 July 2022

11 July 2022

Carla E M Hollak

9

Carla E M

Creative Commons Attribution 4.0 International

Hollak

2 references

8 July 2022

11 July 2022

language of work or name

English

0 references

publication date

2007

0 references

published in

PLOS One

0 references

volume

2

0 references

issue

7

0 references

page(s)

e598

0 references

copyright license

start time

11 July 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

A simple method for the isolation and purification of total lipides from animal tissues

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Rapid method of preparation of lysoglycosphingolipids and their confirmation by delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Fabry's Disease: Alpha-Galactosidase Deficiency

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

12 September 2017

Pediatric Fabry disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

30 May 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0000598

Fabry disease: overall effects of agalsidase alfa treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0000598

The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0000598

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0000598

Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0000598

Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0000598

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0000598

Enzyme replacement therapy and renal function in 201 patients with Fabry disease.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1913555

Enzyme-replacement therapy for Anderson-Fabry disease

29 November 2018

1 reference

12 December 2020

Enzyme replacement in Anderson-Fabry disease

1 reference

12 December 2020

Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease

1 reference

12 December 2020

Enzymatic Defect in Fabry's Disease

1 reference

12 December 2020

Fabry disease: Detection of heterozygotes by examination of glycolipids in urinary sediment

1 reference

12 December 2020

Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study

1 reference

12 December 2020

Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran

1 reference

12 December 2020

Clinical benefit of enzyme replacement therapy in Fabry disease

1 reference

12 December 2020

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

12 December 2020

Reliability of echocardiographic assessment of left ventricular structure and function

1 reference

12 December 2020